Hemoglobinopathy is a type of severe bleeding disorder and can happen at any age. It is a medical condition wherein the red blood cells do not properly carry oxygen to the parts of the body. This results in severe swelling, damage, and bleeding. There are different types of hemoglobinopathy including regional blood disease (RBD), nonbacterial bleeding syndrome (NBS), leukemia, myelodysplasia, and polymyalgia rheumatic. With the various treatments for hemoglobinopathy, it is possible for them to be managed and even prevented. As far as the regional footprint is concerned, North America seems to be gaining significant traction in the hemoglobinopathy treatment market. This is because there is a high prevalence of hemoglobinopathies in North America. As per the CDC, 15.5 cases per 1,000 births in the U.S. are found with sickle cell disease. On the contrary, Asia Pacific is exhibiting promising signs in regards to the adoption of the said treatment due to improving healthcare infrastructure.
The most common medicines that are used for hemoglobinopathy treatment are ACE inhibitors. However, it should be noted that there are other forms of these drugs like anti-angiotensin II inhibitors, anti-platelet agents, and anti-precursors. They are all used to correct the processes or problems that are involved in hemoglobinopathy. Some of these drugs can cause undesirable side effects though. To minimize the risks of these side effects, doctors would usually prescribe the non-drug treatments like beta-blockers, diuretics, nitroglycerine, and calcium channel blockers. That being said, certain factors can still limit the adoption of the said treatment. One of the major hurdles is the low awareness regarding hemoglobinopathies. Besides, higher capital expenditure and inadequate availability of skilled resources can inhibit the growth of the hemoglobinopathy treatment market.
Another important treatment for hemoglobinopathy is exercise. Exercises such as swimming, walking, and biking can strengthen the heart and lower the blood pressure in the body. Key players operating in the healthcare and biopharmaceutical industry are focused on research and development activities. The primary emphasis on the development of effective hemoglobinopathy treatment options with a robust pipeline for drug discovery. Therefore, these factors can potentially augment the growth of the hemoglobinopathy treatment market.